Pure Global AI
NCT06281678Not yet recruiting

A Study of IBI363 in Subjects With Advanced Solid Malignancies

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
IBI363
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Fairway, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2024
End date
Dec 31, 2026
Enrollment
160 participants
Primary outcome

Objective response rate (ORR)

Summary

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety
 and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid
 malignancies.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06281678
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06281678 through Pure Global AI's free database. This Phase 2 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.